Open Access<p>Synergistic Combination Chemotherapy of Lung Cancer: Cisplatin and Doxorubicin Conjugated Prodrug Loaded, Glutathione and pH Sensitive Nanocarriers</p>
Author(s) -
Yonglong Jin,
Yi Wang,
Xiguang Liu,
Jing Zhou,
Xintong Wang,
Hui Feng,
Hong Liu
Publication year - 2020
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s260253
Subject(s) - nanocarriers , prodrug , chemistry , zeta potential , doxorubicin , in vivo , pharmacology , cisplatin , cytotoxicity , mtt assay , glutathione , drug delivery , chemotherapy , in vitro , materials science , biochemistry , organic chemistry , medicine , nanoparticle , nanotechnology , biology , surgery , microbiology and biotechnology , enzyme
Prodrug technology-based combination drug therapy has been exploited as a promising treatment strategy to achieve synergistic lung cancer therapy, reduce drug dose, and decrease side effects. In the present study, we synthesized a pH and glutathione (GSH) sensitive prodrug, cisplatin (CIS) and doxorubicin (DOX) conjugates (CIS-DOXp). CIS-DOXp was loaded by nanocarriers and delivered into the tumor site.